Loading…

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

Saved in:
Bibliographic Details
Published in:HemaSphere 2023-08, Vol.7 (S3), p.e8073255-n/a
Main Authors: Choquet, Sylvain, Clark, Andrew, Renard, Cécile, Uttenthal, Ben, Chaganti, Sridhar, Ulrich Trappe, Ralf, Comoli, Patrizia, Duan, Xinyuan, Xing, Baodong, Wu, Charley, Gamelin, Laurence, Terwey, Jan‐Henrik, Friedetzky, Anke, Dierickx, Daan
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page n/a
container_issue S3
container_start_page e8073255
container_title HemaSphere
container_volume 7
creator Choquet, Sylvain
Clark, Andrew
Renard, Cécile
Uttenthal, Ben
Chaganti, Sridhar
Ulrich Trappe, Ralf
Comoli, Patrizia
Duan, Xinyuan
Xing, Baodong
Wu, Charley
Gamelin, Laurence
Terwey, Jan‐Henrik
Friedetzky, Anke
Dierickx, Daan
description
doi_str_mv 10.1097/01.HS9.0000972440.80732.55
format article
fullrecord <record><control><sourceid>wiley_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aa027855236c4b1ea54bea970adf8954</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aa027855236c4b1ea54bea970adf8954</doaj_id><sourcerecordid>HEM3BF07457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2857-e3f1a8f795ef1055ca9ca55f41a9d74dce40eede7dce84028ebddf8e545ce6873</originalsourceid><addsrcrecordid>eNqVkk9u1DAYxSMEElXpHSxWIDTBTuxx3A3KeL5pImWSKHEKXVmexCmppp0qaUHdcQQOxGk4CZ4OArrEG_v7835-i-d5rwn2CRb8PSZ-UgsfuyN4QCn2I8zDwGfsmXcUMB7MREDJ83_eL72Tabpy-0QIMQ_4kfejJGEUnSJYrUCq9BxyqGsU50tUxytQF6holCzWUKM0R2WsUshVjT6mKkGwOH-HSpUtkaogVrA8tOMsK84cJpX7jZ_fvtclyHTlSuUKCVmG0vW6yQuVQBWXF-iNiheQgcygcdO3qMmXUDkLCD6VzojjxlLuXZVVcVbF670TaKqihFfei95sJ3vy-z72GudZJjPnIJVxNmuDiPGZDXtiop4LZnuCGWuNaA1jPSVGdJx2raXY2s5y94ooDiK76bo-soyy1s4jHh576YHb7cyVvh2HazM-6J0Z9GNjN15qM94N7dZqY3DAI8aCcN7SDbGG0Y01gmPjiIJRx_pwYN3eb66t-_HmbjTbJ9Cnk5vhs77cfdEE0xDPBXGE0wOhHXfTNNr-j5hgvQ-GxkS7YOi_wdCPwdCMObE8iL8OW_vwH0qdwDpcrDCnjIe_AC9ltOI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</title><source>Wiley Online Library Open Access</source><source>PubMed Central</source><creator>Choquet, Sylvain ; Clark, Andrew ; Renard, Cécile ; Uttenthal, Ben ; Chaganti, Sridhar ; Ulrich Trappe, Ralf ; Comoli, Patrizia ; Duan, Xinyuan ; Xing, Baodong ; Wu, Charley ; Gamelin, Laurence ; Terwey, Jan‐Henrik ; Friedetzky, Anke ; Dierickx, Daan</creator><creatorcontrib>Choquet, Sylvain ; Clark, Andrew ; Renard, Cécile ; Uttenthal, Ben ; Chaganti, Sridhar ; Ulrich Trappe, Ralf ; Comoli, Patrizia ; Duan, Xinyuan ; Xing, Baodong ; Wu, Charley ; Gamelin, Laurence ; Terwey, Jan‐Henrik ; Friedetzky, Anke ; Dierickx, Daan</creatorcontrib><identifier>ISSN: 2572-9241</identifier><identifier>EISSN: 2572-9241</identifier><identifier>DOI: 10.1097/01.HS9.0000972440.80732.55</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams &amp; Wilkins</publisher><ispartof>HemaSphere, 2023-08, Vol.7 (S3), p.e8073255-n/a</ispartof><rights>Copyright © 2023 The Author(s).</rights><rights>Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430691/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430691/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11541,27901,27902,46027,46451,53766,53768</link.rule.ids></links><search><creatorcontrib>Choquet, Sylvain</creatorcontrib><creatorcontrib>Clark, Andrew</creatorcontrib><creatorcontrib>Renard, Cécile</creatorcontrib><creatorcontrib>Uttenthal, Ben</creatorcontrib><creatorcontrib>Chaganti, Sridhar</creatorcontrib><creatorcontrib>Ulrich Trappe, Ralf</creatorcontrib><creatorcontrib>Comoli, Patrizia</creatorcontrib><creatorcontrib>Duan, Xinyuan</creatorcontrib><creatorcontrib>Xing, Baodong</creatorcontrib><creatorcontrib>Wu, Charley</creatorcontrib><creatorcontrib>Gamelin, Laurence</creatorcontrib><creatorcontrib>Terwey, Jan‐Henrik</creatorcontrib><creatorcontrib>Friedetzky, Anke</creatorcontrib><creatorcontrib>Dierickx, Daan</creatorcontrib><title>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</title><title>HemaSphere</title><issn>2572-9241</issn><issn>2572-9241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>DOA</sourceid><recordid>eNqVkk9u1DAYxSMEElXpHSxWIDTBTuxx3A3KeL5pImWSKHEKXVmexCmppp0qaUHdcQQOxGk4CZ4OArrEG_v7835-i-d5rwn2CRb8PSZ-UgsfuyN4QCn2I8zDwGfsmXcUMB7MREDJ83_eL72Tabpy-0QIMQ_4kfejJGEUnSJYrUCq9BxyqGsU50tUxytQF6holCzWUKM0R2WsUshVjT6mKkGwOH-HSpUtkaogVrA8tOMsK84cJpX7jZ_fvtclyHTlSuUKCVmG0vW6yQuVQBWXF-iNiheQgcygcdO3qMmXUDkLCD6VzojjxlLuXZVVcVbF670TaKqihFfei95sJ3vy-z72GudZJjPnIJVxNmuDiPGZDXtiop4LZnuCGWuNaA1jPSVGdJx2raXY2s5y94ooDiK76bo-soyy1s4jHh576YHb7cyVvh2HazM-6J0Z9GNjN15qM94N7dZqY3DAI8aCcN7SDbGG0Y01gmPjiIJRx_pwYN3eb66t-_HmbjTbJ9Cnk5vhs77cfdEE0xDPBXGE0wOhHXfTNNr-j5hgvQ-GxkS7YOi_wdCPwdCMObE8iL8OW_vwH0qdwDpcrDCnjIe_AC9ltOI</recordid><startdate>20230808</startdate><enddate>20230808</enddate><creator>Choquet, Sylvain</creator><creator>Clark, Andrew</creator><creator>Renard, Cécile</creator><creator>Uttenthal, Ben</creator><creator>Chaganti, Sridhar</creator><creator>Ulrich Trappe, Ralf</creator><creator>Comoli, Patrizia</creator><creator>Duan, Xinyuan</creator><creator>Xing, Baodong</creator><creator>Wu, Charley</creator><creator>Gamelin, Laurence</creator><creator>Terwey, Jan‐Henrik</creator><creator>Friedetzky, Anke</creator><creator>Dierickx, Daan</creator><general>Lippincott Williams &amp; Wilkins</general><general>Wiley</general><scope>24P</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230808</creationdate><title>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</title><author>Choquet, Sylvain ; Clark, Andrew ; Renard, Cécile ; Uttenthal, Ben ; Chaganti, Sridhar ; Ulrich Trappe, Ralf ; Comoli, Patrizia ; Duan, Xinyuan ; Xing, Baodong ; Wu, Charley ; Gamelin, Laurence ; Terwey, Jan‐Henrik ; Friedetzky, Anke ; Dierickx, Daan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2857-e3f1a8f795ef1055ca9ca55f41a9d74dce40eede7dce84028ebddf8e545ce6873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choquet, Sylvain</creatorcontrib><creatorcontrib>Clark, Andrew</creatorcontrib><creatorcontrib>Renard, Cécile</creatorcontrib><creatorcontrib>Uttenthal, Ben</creatorcontrib><creatorcontrib>Chaganti, Sridhar</creatorcontrib><creatorcontrib>Ulrich Trappe, Ralf</creatorcontrib><creatorcontrib>Comoli, Patrizia</creatorcontrib><creatorcontrib>Duan, Xinyuan</creatorcontrib><creatorcontrib>Xing, Baodong</creatorcontrib><creatorcontrib>Wu, Charley</creatorcontrib><creatorcontrib>Gamelin, Laurence</creatorcontrib><creatorcontrib>Terwey, Jan‐Henrik</creatorcontrib><creatorcontrib>Friedetzky, Anke</creatorcontrib><creatorcontrib>Dierickx, Daan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>HemaSphere</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choquet, Sylvain</au><au>Clark, Andrew</au><au>Renard, Cécile</au><au>Uttenthal, Ben</au><au>Chaganti, Sridhar</au><au>Ulrich Trappe, Ralf</au><au>Comoli, Patrizia</au><au>Duan, Xinyuan</au><au>Xing, Baodong</au><au>Wu, Charley</au><au>Gamelin, Laurence</au><au>Terwey, Jan‐Henrik</au><au>Friedetzky, Anke</au><au>Dierickx, Daan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE</atitle><jtitle>HemaSphere</jtitle><date>2023-08-08</date><risdate>2023</risdate><volume>7</volume><issue>S3</issue><spage>e8073255</spage><epage>n/a</epage><pages>e8073255-n/a</pages><issn>2572-9241</issn><eissn>2572-9241</eissn><cop>Philadelphia, PA</cop><pub>Lippincott Williams &amp; Wilkins</pub><doi>10.1097/01.HS9.0000972440.80732.55</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2572-9241
ispartof HemaSphere, 2023-08, Vol.7 (S3), p.e8073255-n/a
issn 2572-9241
2572-9241
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_aa027855236c4b1ea54bea970adf8954
source Wiley Online Library Open Access; PubMed Central
title P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T04%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P1388:%20EFFECTIVENESS%20AND%20SAFETY%20OUTCOMES%20IN%20PATIENTS%20WITH%20EBV+%20PTLD%20TREATED%20WITH%20ALLOGENEIC%20EBV%E2%80%90SPECIFIC%20T%E2%80%90CELL%20IMMUNOTHERAPY%20(TABELECLEUCEL)%20UNDER%20AN%20EXPANDED%20ACCESS%20PROGRAM%20IN%20EUROPE&rft.jtitle=HemaSphere&rft.au=Choquet,%20Sylvain&rft.date=2023-08-08&rft.volume=7&rft.issue=S3&rft.spage=e8073255&rft.epage=n/a&rft.pages=e8073255-n/a&rft.issn=2572-9241&rft.eissn=2572-9241&rft_id=info:doi/10.1097/01.HS9.0000972440.80732.55&rft_dat=%3Cwiley_doaj_%3EHEM3BF07457%3C/wiley_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2857-e3f1a8f795ef1055ca9ca55f41a9d74dce40eede7dce84028ebddf8e545ce6873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true